Ethical considerations in orphan drug approval and use

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 153-155

  Kesselheim, A S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMTUZUMAB OZOGAMICIN; IMATINIB; MIDODRINE; ORPHAN DRUG;

ACT; BENEFICENCE; CHILDHOOD LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; JUSTICE; MEDICAL ETHICS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; INFORMED CONSENT; ORPHAN DRUG PRODUCTION; PRODUCT SURVEILLANCE, POSTMARKETING; RARE DISEASES; RISK ASSESSMENT;

EID: 84864127384     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.92     Document Type: Review

References (10)

1. Coté, T., Kelkar, A., Xu, K., Braun, M.M. & Phillips, M.I. Orphan products: an emerging trend in drug approvals. Nat. Rev. Drug Discov. 9, 84 (2010).
2. Kesselheim, A.S. Innovation and the Orphan Drug Act, 1983-2009: the regulatory and clinical characteristics of approved orphan drugs. In Accelerating Rare Diseases Research and Orphan Product Development (eds. Field, M.J. & Boat, T.F.) (National Academy Press, Washington, DC, 2010).
3. Adequate and well-controlled studies. Title 21 Code of Federal Regulations, Pt. 314, Sec. 126, 2007.
4. Kesselheim, A.S., Myers, J.A. & Avorn, J. Characteristics of clinical trials to support approval of orphan vs. nonorphan drugs for cancer. JAMA 305, 2320-2326 (2011).
5. Mitsumoto, J., Dorsey, E.R., Beck, C.A., Kieburtz, K. & Griggs, R.C. Pivotal studies of orphan drugs approved for neurological diseases. Ann. Neurol. 66, 184-190 (2009).
6. US Food and Drug Administration. Mylotarg (gemtuzumab ozogamicin): market withdrawal 〈http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm216458.htm〉 (21 June 2010).
7. Richey, E.A. et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J. Clin. Oncol. 27, 4398-4405 (2009).
8. Harris, G. F.D.A. backtracks and returns drug to market. New York Times, 3 September 2010, p. A11.
9. Schaeffer, M.H. et al. The impact of disease severity on the informed consent process in clinical research. Am. J. Med. 100, 261-268 (1996). (Pubitemid 26111622)
10. Herper, M. The world's most expensive drugs. Forbes, 22 February 2010 〈http://www.forbes. com/2010/02/19/expensive-drugs-costbusiness-healthcare- rare-diseases.html〉.